Application of advanced thermal analysis for characterization of crystalline and amorphous phases of carvedilol

The Impact of Various Poly(vinylpyrrolidone) Polymers on the Crystallization Process of Metronidazole

“…According to previous literature reports [ 44 , 74 , 75 , 76 ], the endothermic event at higher T corresponds to the melting of the API, while the exothermic one at lower T is attributed to the crystallization of MTZ. At this point, it is worth mentioning that inspired by studies demonstrating that the cooling rate of a sample significantly influences the phase transitions and makes it possible to transform the crystalline API into the amorphous form [ 77 , 78 , 79 ], we have made attempts to supercool/vitrify MTZ at various . Unfortunately, our efforts were unsuccessful.…”

Effect of Polyamorphism on the Morphology, Dissolution, and Stability of Olaparib

“…Although crystalline form is the most commonly used solid form in the development of solid formulations, a promising alternative method is to convert crystalline drugs into amorphous states. , Compared with a crystalline form, in which molecules are arranged in both long-range order and short-range order, molecules in an amorphous form are assembled in a long-range disordered and short-range ordered manner, resulting in higher energy state and improved apparent solubility, dissolution rate, and bioavailability of a given drug. − Therefore, amorphous technology has become an important strategy for the formulation and development of insoluble drugs. At present, a variety of insoluble drugs, such as cefuroximeaxetil, quinapril hydrochloride, troglitazone, and zafirlukast, have been developed and marketed in amorphous forms. − …”

Ultrasound-assisted continuous crystallization of metastable polymorphic pharmaceutical in a slug-flow tubular crystallizer

“…1 ) as the model compound, which is used to clinically treat congestive heart failure [33] , hypertension [34] , and myocardial infarction [35] . CVD is a third-generation non-selective beta and alpha-1 blocker belonging to BCS class II APIs [34] , [35] , [36] , [37] , [38] , as shown in Fig. 1 .…”